Height and Bone Phenotype of 22q11.2 Deletion Syndrome: Lessons from the Gene Analysis of Three Cases

Bu Kyung Kim¹, Young Bae Sohn², Sang-Jin Park¹, Shin-Young Yim³ and Yoon-Sok Chung²,⁵*  
¹Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea  
²Departments of Medical Genetics, Ajou University School of Medicine, Suwon, Korea  
³MG Med, Inc. Seoul, Korea  
⁴Physical Medicine and Rehabilitation, Ajou University School of Medicine, Suwon, Korea  
⁵Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea

This report describes three cases of 22q11.2 deletion syndrome (22q11.2DS) diagnosed by array comparative genomic hybridization with final adult height and bone phenotype. The cases involved a 57-year-old woman with hypocalcemic seizure, an 18-year-old man with short stature, and a 24-year-old woman incidentally diagnosed as 22q11.2DS. The first two patients revealed short stature and low bone mineral density, and their deletion sites included the TBX1. The third patient had normal stature and normal bone mineral density, and the deletion site did not include the TBX1. The deletion of specific genes including the TBX1 could be an important factor of skeletal development including height and bone mineral density of 22q11.2DS.

Key words: 22q11.2 deletion syndrome, Height, Bone

Introduction

Deletion 22q11.2 (22q11.2DS) is the most common micro-deletion syndrome in human, with a minimum prevalence rate of one in 4,000 live births.¹,²) Nomenclatures for 22q11.2DS include velocardiofacial syndrome, DiGeorge syndrome, and CATCH22 (cardiac anomaly, abnormal face, thymic hypoplasia, cleft palate, hypocalcemia) syndrome. These various nomenclatures reflect the myriad of clinical features.³⁻⁶) Short stature is one of the most common clinical features of 22q11.2DS. However, it is unclear whether short stature is an intrinsic manifestation of this syndrome, or whether it is secondary to other clinical features.⁷⁻⁸) Herein we report three cases of 22q11.2DS diagnosed by whole genome array comparative genomic hybridization (array CGH) using commercially available array-CGH slides (MACArray Karyo 1440 BAC-chip; Macrogen, Seoul, Korea). We also investigated the genotype-phenotype correlation, especially focused on genomic deletion size, final adult height, and bone mineral density (BMD).

Case

The first case was a 57-year-old woman who visited the emergency room due to seizure. She had a 2-week history of tetany on both hands. There was no previous history of seizure. Laboratory testing results revealed hypocalcemia (5.3 mg/dL; 8.2⁻10.23 mg/dL), elevated serum phosphate (5.5 mg/dL; 2.7⁻4.5 mg/dL), and hypocalcemia (5.3 mg/dL; 8.2⁻10.23 mg/dL).
mg/dL), and low values for parathyroid hormone (8 pg/mL; 11–62 pg/mL), and 25-OH-Vitamin D₂ (2.1 ng/mL; 9.0–37.6 ng/mL). She had left kidney agenesis and hearing impairment in both ears (right: 50 dB, left: 40 dB). The intelligence quotient (IQ) was below average (<85); especially, verbal IQ was delayed. Osteoporosis was evident, with a BMD T score of -4.0. The patient's height was 150 cm and her weight was 43 kg lower than the 3rd percentile. After supplementation with calcium and vitamin D, the patient’s mental status became alert and tetany was improved. A 0.9 Mb deletion (19,030,620-19,962,449) (Fig. 1A) contained TBX1 was detected on chromosome 22q11.2 (Fig. 2A).

The second case was an 18-year-old man who visited an outpatient department with the chief complaint of short stature. His past history included cardiac surgery at 1-month-of-age, diagnosis as velopharyngeal insufficiency at the age of 6, and three incidents of fracture. His height was 156.5 cm lower than the 3rd percentile and weight was 51 kg (3rd to 5th percentile). Pubertal status was normal. The level of 25-OH-Vitamin D₃ was low (6.7 ng/mL) and other laboratory test was normal. Serum IGF-I level was normal and the result of insulin-induced growth hormone stimulation test was normal. Although his bone age was 18 years, his lumbar spine BMD was 0.844 g/cm² and femoral neck BMD was 0.754 g/cm², which were lower than age matched reference values (18-year-old male spine 1.154±0.098 g/cm², femur neck 1.106±0.119 g/cm²). A 2.1 Mb deletion (19,030,620-21,176,652) (Fig. 1B) contained the TBX1 was detected on chromosome 22q11.2 (Fig. 2B).

The last case was a 24-year-old woman who visited department of Physical Medicine and Rehabilitation to obtain a medical certificate of disability. She had a growth delay until 3-months-of-age and feeding difficulty. She had a history of surgery for a cleft palate at 9-years-of-age. The level of 25-OH-Vitamin D₂ was low (5.6 ng/mL) and other laboratory test was normal. She had a speech and language developmental disorder. Her BMD was normal, her height was 165.9 cm (75th to 90th percentile) and her weight was 74.7 kg (more than 95th percentile). A 0.3 Mb deletion (19,030,620-19,372,279) (Fig. 1C) did not contain the TBX1 was detected on chromosome 22q11.2 (Fig. 2C).

Discussion

Although short stature is one of the most common clinical features of 22q11.2DS, the mechanism is unclear. In infancy, the growth pattern in the 22q11.2DS is slow. Several studies reported final adult heights are usually in the normal range. However, an analysis of the growth charts from 188 patients reported that adults with this syndrome remained below the 2nd percentile.

![Fig. 1. Array CGH profile from chromosome 22 shows a deletion on the long arm. Arrow indicates a deletion at chromosome 22q11.2. The position of the array CGH was based on NCBI human genome build 37 (GRCh37/hg19; Feb. 2009). (A) The internal boundary is 19,030,620-19,962,449, and its size is 0.9 Mb. (B) The internal boundary is 19,030,620-21,176,652, and its size is 2.1 Mb. (C) The internal boundary is 19,030,620-19,372,279, and its size is 0.3 Mb.](image-url)
for the normal population. Average heights for male and female adults were 167.2 cm and 158.2 cm, respectively. Another paper reported that final adult heights were 166 cm and 152 cm, respectively. Two patients of this report were shorter than these reference values. These two cases had low BMD with or without hypoparathyroidism and hypocalcemia.

Bone mass and metabolism of the patients with 22q11.2DS are almost unknown. Stagi et al. reported that patients with 22q11.2DS had reduced bone mass measured by bone mineral apparent density. The reduction of bone mass worsened with age in adults. The authors explained that lower bone mass was probably due to reduced bone modeling during childhood, which would result in a reduced peak bone mass, posing a significant risk of impaired bone mass in adulthood. Hypoparathyroidism and hypocalcemia are also frequent manifestations in 22q11.2DS, although are the insufficient cause of reduced BMD. Post-surgical hypoparathyroidism as well as idiopathic hypoparathyroidism increases BMD.

Therefore, the causes of reduced bone mass in 22q11.2DS may be multifocal.

Previous studies reported 50% to 80% of the variance in bone mass is genetically determined. A Caucasian genome wide linkage study suggested lumbar spine BMD is affected by chromosome 22q11-12. Therefore, deletion of 22q11 may be an important factor of reduced BMD. The TBX1, is most important factor of pathogenesis of 22q11.2DS. TBX1 is expressed at cardiac outflow, pharyngeal mesenchyme, and endodermal pouch. Therefore, deletion of this gene could lead to most of the phenotypes of 22q11.2DS. TBX1 is also expressed in the sclerotome, which differentiates to the spinal column. Fulcoli et al. reported that TBX1 contributes to the BMP/Smad1 pathway, which could affect osteoblast differentiation. These results suggest TBX1 could be a factor of reduced BMD of 22q11.2DS. The third case in this paper was of normal stature and had normal BMD. Her deletion site did not include the TBX1.

The association TBX1 and short stature is already known however the mechanism has not been understood. We reviewed all common gene of two cases with short stature and low BMD. There was no gene which has the possibility of direct effect to bone metabolism except TBX1. Here, we report only three cases, so it may be incidental.

Nevertheless, the possibility of the influence of TBX1 to bone metabolism is interesting. Short stature could be a result of low bone mass, influenced by the TBX1. Analyses of gene array and matched clinical phenotype of 22q11.2DS in large number of patients could increase the understanding of this important genetic disorder.

References

5. Shprintzen RJ. Velo-cardio-facial syndrome: 30 Years of study. Dev


